Filing Details
- Accession Number:
- 0002001011-24-000053
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-17 19:59:50
- Reporting Period:
- 2024-05-15
- Accepted Time:
- 2024-05-17 19:59:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1905248 | Octavio Espinoza | 555 Heritage Drive Suite 200 Jupiter FL 33458 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-05-15 | 5,873 | $86.01 | 23,882 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-16 | 2,264 | $86.00 | 21,618 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-05-17 | 206 | $57.22 | 21,824 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-05-17 | 1,544 | $63.62 | 23,368 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-05-17 | 145 | $68.74 | 23,513 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-05-17 | 5,022 | $52.84 | 28,535 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-17 | 5,022 | $86.67 | 23,513 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-17 | 134 | $86.65 | 23,379 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-05-17 | 206 | $0.00 | 206 | $57.22 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2024-05-17 | 1,544 | $0.00 | 1,544 | $63.62 |
| Common Stock | Incentive Stock Option (right to buy) | Disposition | 2024-05-17 | 145 | $0.00 | 145 | $68.74 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2024-05-17 | 5,022 | $0.00 | 5,022 | $52.84 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,516 | 2030-10-01 | No | 4 | M | Direct | |
| 18,456 | 2032-12-13 | No | 4 | M | Direct | |
| 0 | 2029-02-11 | No | 4 | M | Direct | |
| 16,179 | 2032-05-05 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- As per the separation of OmniAb Inc. from the issuer, 4,096 stock options were vested and exercisable as of November 1, 2022, whereas 3,766 options vest in 23 substantially equal monthly installments beginning on December 1, 2022.
- Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter.
- The stock option vests as to 50% of the underlying shares on January 11, 2023 and as to the remaining on February 11, 2023.
- The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
Billionaire Hedge Funds
